The MyGenera™ platform, through its bioinformatic process based on the company’s proprietary intellectual property, enables the rapid identification of new AG-PNAs with their unique mechanism of action and is applicable to all therapeutic areas where it is possible to act by silencing individual disease-causing genes.
The innovation of
Gene-specific therapies and their mechanism of action
The MyGenera™ platform enables the rapid identification of new anti-gene oligonucleotide (Ag-PNA) drug candidates (indicated in red) that specifically block the activity of the disease-causing gene directly at its source.
The new class of Ag-PNA drugs is characterized by a short sequence of chemically modified DNA that acts at the source on a single pathological target gene, directly inhibiting the transcription process.
This approach differs from the traditional “antisense” oligonucleotide approach, as it inhibits DNA transcription into RNA (anti-gene approach) instead of inhibiting RNA translation into protein (antisense approach).
Applications
The uniqueness of the MyGenera platform’s mechanism of action is applicable to all therapeutic areas where it is possible to act by silencing individual disease-causing genes.
01
Oligonucleotide
anti-gene specifico
(Oligo AG-PNA)
Target gene (two copies per cell)
The gene-specific oligonucleotide acts by selectively and strongly binding to a strand of the complementary DNA sequence contained in the target gene. The binding occurs on a strand of the open structure of the active target gene’s DNA, thereby blocking its transcription.
02
Pharmacological Action
AG-PNA specifically inhibits the transcription of the target gene, blocking the production of thousands of mRNA copies.
03
Pharmacological Action
As a result, the inhibition of transcription also leads to the inhibition of the production of thousands of protein copies (translation inhibition).
English 
Italian